Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.

Journal of experimental & clinical cancer research : CR - 16 May 2026

Mayr Lisa, Mager Leah, Gabler-Pamer Lisa, Kirchhofer Dominik, Freund Julia, Schwark Kallen, Lau Benison, Machreich Sarah, Senfter Daniel, Neumüller Mia, Lang Alexandra, Madlener Sibylle, Laemmerer Anna, Bruckner Katharina, Jaunecker Carola N, Robl Bernhard, Walter Romina, Schueler Julia, Peyrl Andreas, Azizi Amedeo A, Dorfer Christian, Roessler Karl, Spiegl-Kreinecker Sabine, Haberler Christine, Federico Aniello, Gopisetty Apurva, Schleiermacher Gudrun, Pfister Stefan M, Geoerger Birgit, Chesler Louis, Vassal Gilles, Kool Marcel, Müllauer Leonhard, Koschmann Carl, Berger Walter, Gojo Johannes, Lötsch Daniela

Abstract excerpt

BACKGROUND: BRAF-altered pediatric high-grade gliomas (pHGG) harbor a dismal prognosis. Although targeted therapy with BRAF and MEK inhibitors provides initial benefit, resistance emerges rapidly in clinical practice indicating an urgent need for improved therapeutic strategies. As BRAF mutations frequently co-occur with homozygous CDKN2A/B loss, we investigated CDK4/6 inhibition as a rational therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aminopyridines

Share to Benzimidazoles

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Epithelial-Mesenchymal Transition

Share to Pyridones

Share to Pyrimidinones

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 42143334
DOI: 10.1186/s13046-026-03725-3
PMCID: PMC13348095

Genes

BRAF
CDK4
CDKN2A
CD44

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.PMID 42143334Read ↗

Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.Semantic proximity Read ↗

Patient-Derived Orthotopic Xenografts and Cell Lines from Pediatric High-Grade Glioma Recapitulate the Heterogeneity of Histopathology, Molecular Signatures, and Drug ResponseSemantic proximity Read ↗

Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.Semantic proximity Read ↗

Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical ModelsSemantic proximity Read ↗

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.Semantic proximity Read ↗

Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma.Semantic proximity Read ↗

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.Semantic proximity Read ↗

BRAF and MEK Targeted Therapies in Pediatric Central Nervous System TumorsSemantic proximity Read ↗

A High-Throughput In Vitro Drug Screen in a Genetically Engineered Mouse Model of Diffuse Intrinsic Pontine Glioma Identifies BMS-754807 as a Promising Therapeutic AgentSemantic proximity Read ↗

Cooperative interactions of BRAF <sup>V600E</sup> kinase and <i>CDKN2A</i> locus deficiency in pediatric malignant astrocytoma as a basis for rational therapySemantic proximity Read ↗

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.Semantic proximity Read ↗

Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.